The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.
Theseus Pharmaceuticals, a US-based targeted oncology drug developer backed by pharmaceutical firm Ariad Pharmaceuticals, has raised $160m in its initial public offering.
The offering involved the sale of approximately 10 million shares on the Nasdaq Global Select Market priced at $16 apiece, at the top of the IPO’s $14 to $16 range. The share price valued it at $600m.
Theseus is developing therapies targeting a range of cancers through tyrosine kinase inhibitors that also allow for the prediction of…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
